Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 15 min ago
Peer-reviewedCC BY 4.0International Journal of Obesity (2005)

Utilization and outcomes of nutrient-stimulated hormone therapies in patients undergoing bariatric surgery

  • Claudia R. Villatoro Santos1
  • Hector D. Estrada Tock2
  • Haoran Tang3
  • Laura N. McEwen4
  • Andrew Kraftson4
  • William H. Herman4,5
  • Amy E. Rothberg4
5 affiliations
  1. 1Division of Endocrinology, Metabolism & Lipid Research, Department of Medicine, Washington University School of Medicine, St. Louis, MO USA
  2. 2School of Information, University of Michigan, Ann Arbor, MI USA
  3. 3Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI USA
  4. 4Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, MI USA
  5. 5Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI USA
Read full textPDFDOICite

Abstract

Objective: To describe the impact of nutrient-stimulated hormone (NuSH) therapies on weight loss by bariatric surgery type, diabetes status, and timing of initial NuSH prescription.

Methods: Retrospective study of 1638 adults who underwent bariatric surgery at a single academic medical center between 2015 and 2022. Baseline demographics, NuSH therapy prescriptions, and follow-up weights were obtained from electronic health records. We calculated percent total weight loss (%TWL) over time using linear mixed models.

Results: Patients who underwent Roux-en-Y gastric bypass (RYGB) had greater %TWL compared to those who underwent sleeve gastrectomy (SG). Those without diabetes had greater %TWL compared to those with diabetes. At 72 months, adjusted average %TWL was highest in patients who received NuSH prescriptions both before and after surgery (22.7%, 95% CI: 17.9–27.5), followed by those with prescriptions only after surgery (19.9%, 95% CI: 18.3–21.4) and those without prescriptions (19.6%, 95% CI: 18.1–21.2). The greatest %TWL was seen in patients who had prescriptions within 6 months after surgery.

Conclusion: Individuals who underwent RYGB and who did not have diabetes had the highest %TWL. Receiving a NuSH prescription both before and after surgery and early NuSH initiation were associated with the greatest %TWL.

Related

  1. Impact of Remote Symptom Monitoring on Acute Care Utilization in Patients with Advanced Cancer Undergoing Phase I Therapies: Secondary Analysis of a Randomized Clinical Trial
    Jack Stover, Matthew Meranda, Ishwaria M. Subbiah +5
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  2. Post–Acute Care Facility Utilization and Outcomes Among Medicare Beneficiaries Undergoing Inpatient Cancer Surgery
    Daniel E. Lage, Mary Beth Landrum, Alex Melamed +3
    JAMA Network OpenPeer-reviewedCC BY-NC-NDFull textOncologyCrossrefEurope PMCPMC
  3. Dual benefit of esketamine-based opioid-free anesthesia on postoperative pain and mental health outcomes in patients undergoing bariatric surgery: a randomized controlled trial.
    Chunxia Huang, Zichun Guan, Sheng Wang +12
    Translational psychiatryPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCDOAJ
  4. Trends in the utilization of minimally invasive therapies for overactive bladder among older adults: a national Medicare study
    Adam Crow, Lufan Wang, Abigail Shatkin-Margolis +5
    UrologyPeer-reviewedCC BYFull textGeneral medicinePMC
  5. Nutritional Risk and Unmet Nutritional Need in Ambulatory Patients Undergoing Systemic Anti-Cancer Therapies.
    Amy McLuskie, Karen Angel, Matthew Maddocks +4
    Journal of human nutrition and dietetics : the official journal of the British Dietetic AssociationPeer-reviewedCC BYFull textPhysiologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{santos2026utilization,
  title = {{Utilization and outcomes of nutrient-stimulated hormone therapies in patients undergoing bariatric surgery}},
  author = {Claudia R. Villatoro Santos and Hector D. Estrada Tock and Haoran Tang and Laura N. McEwen and Andrew Kraftson and William H. Herman and Amy E. Rothberg},
  journal = {International Journal of Obesity (2005)},
  year = {2026},
  month = jul,
  doi = {10.1038/s41366-026-02159-3},
  url = {https://doi.org/10.1038/s41366-026-02159-3},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Utilization and outcomes of nutrient-stimulated hormone therapies in patients undergoing bariatric surgery
AU  - Claudia R. Villatoro Santos
AU  - Hector D. Estrada Tock
AU  - Haoran Tang
AU  - Laura N. McEwen
AU  - Andrew Kraftson
AU  - William H. Herman
AU  - Amy E. Rothberg
PY  - 2026
DA  - 2026/07/20
JO  - International Journal of Obesity (2005)
DO  - 10.1038/s41366-026-02159-3
UR  - https://doi.org/10.1038/s41366-026-02159-3
AB  - Objective: To describe the impact of nutrient-stimulated hormone (NuSH) therapies on weight loss by bariatric surgery type, diabetes status, and timing of initial NuSH prescription.  Methods: Retrospective study of 1638 adults who underwent bariatric surgery at a single academic medical center between 2015 and 2022. Baseline demographics, NuSH therapy prescriptions, and follow-up weights were obtained from electronic health records. We calculated percent total weight loss (%TWL) over time using linear mixed models.  Results: Patients who underwent Roux-en-Y gastric bypass (RYGB) had greater %TWL compared to those who underwent sleeve gastrectomy (SG). Those without diabetes had greater %TWL compared to those with diabetes. At 72 months, adjusted average %TWL was highest in patients who received NuSH prescriptions both before and after surgery (22.7%, 95% CI: 17.9–27.5), followed by those with prescriptions only after surgery (19.9%, 95% CI: 18.3–21.4) and those without prescriptions (19.6%, 95% CI: 18.1–21.2). The greatest %TWL was seen in patients who had prescriptions within 6 months after surgery.  Conclusion: Individuals who underwent RYGB and who did not have diabetes had the highest %TWL. Receiving a NuSH prescription both before and after surgery and early NuSH initiation were associated with the greatest %TWL.
SN  - 0307-0565
SN  - 1476-5497
ER  -